B Cell Chronic Lymphocytic Leukemia Clinical Trial
Official title:
Tolerance and Resistance to Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL): Analysis of Real-life Data: "Snapshot" at 3 Years From the End of Ibrutinib ATU. A National Study of the FILO-LLC Group
Assessment of the mutational profile of the residual clone and the distribution of lymphocyte
subpopulations at 3 years of treatment with ibrutinib
This project has an epidemiological part: to establish the percentage of patients, in a
real-life situation, still undergoing treatment 3 years after its initiation, as well as a
biological part: to determine the evolution of the clone and the prevalence of BTK mutations
and PLCg2 in the absence of clinical or biological criteria for scalability.
Observationnal and biological study ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05888701 -
"Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity.
|
||
| Terminated |
NCT03151057 -
Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies
|
Phase 1 | |
| Completed |
NCT00046683 -
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
|
Phase 3 |